脊髓电刺激治疗慢性疼痛的疼痛与功能障碍最小临床重要差值定义
该研究纳入114例接受脊髓电刺激(SCS)治疗的慢性疼痛患者,在术前和术后1年收集结局,采用四种锚定法计算NRS、ODI、BDI、MPQ和PCS的最小临床重要差值(MCID),首次建立MPQ和PCS的MCID范围,并明确NRS、ODI和BDI的1年MCID值,AUC分析显示各量表区分满意患者的准确性显著。
要点
- 首次建立SCS术后MPQ(1-2.3)和PCS(1.9-13.6)的MCID范围。
- 1年MCID值:NRS 0.9-2.7,ODI 3.5-6.9,BDI 2-5.9。
- NRS、ODI、MPQ、PCS的AUC均显著,可区分满意患者。
核心结论
- 首次成功确定MPQ和PCS在SCS术后评估疼痛的MCID值。
- 在12个月时探索了FBSS患者既往6个月建立的ODI、BDI和VAS的MCID值,覆盖SCS最常见适应症。
研究设计与样本
- 收集114例接受SCS治疗的FBSS、复杂区域疼痛综合征和神经病理性疼痛患者的术前和术后1年结局。
- 使用四种锚定法(平均变化法、最小可检测变化法、变化差值计算和ROC分析)计算MCID值。
- 锚定问题为「您对SCS治疗满意吗?」和「您会再次接受SCS手术吗?」,回答「是」为应答者,「否」为无应答者。
主要发现
- 首次建立SCS术后MPQ的MCID范围(1-2.3)和PCS的MCID范围(1.9-13.6)。
- 1年MCID值:NRS范围0.9-2.7,ODI范围3.5-6.9,BDI范围2-5.9。
- AUC值显著:NRS 0.78(p < 0.001),ODI 0.71(p = 0.003),MPQ 0.74(p < 0.001),PCS 0.77(p < 0.001),表明区分满意患者具有显著准确性。
关键数值与推荐
- MPQ的MCID范围为1-2.3,PCS的MCID范围为1.9-13.6。
- NRS的1年MCID范围为0.9-2.7,ODI为3.5-6.9,BDI为2-5.9。
- NRS的AUC为0.78(p < 0.001),ODI为0.71(p = 0.003),MPQ为0.74(p < 0.001),PCS为0.77(p < 0.001)。
临床怎么用
- 这些MCID数据可帮助医生更好地判断患者对SCS治疗的反应和成功情况。
- MPQ和PCS的MCID值可用于SCS术后疼痛评估。
- NRS、ODI和BDI的1年MCID值适用于SCS常见适应症患者的疗效评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Minimal clinically important difference (MCID) thresholds for a limited number of outcome metrics were previously defined for patients with failed back surgery syndrome (FBSS) at 6 months after spinal cord stimulation (SCS). This study aimed to further define MCID values for pain and disability outcomes. Additionally, the authors established 1-year MCID values for outcome measures with previously defined metrics commonly used to assess SCS efficacy. METHODS: Preoperative and 1-year postoperative outcomes were collected from 114 patients who received SCS therapy for FBSS, complex regional pain syndrome, and neuropathic pain. MCID values were established for the numerical rating scale (NRS), Oswestry Disability Index (ODI), Beck Depression Inventory (BDI), McGill Pain Questionnaire (MPQ), and Pain Catastrophizing Scale (PCS). Four established anchor-based methods were utilized to compute MCID values with two anchored questions: "Are you satisfied with SCS therapy?" and "Would you have SCS surgery again?" For each question, patients were categorized as responders if they answered "yes" or as nonresponders if they responded "no." The methodologies utilized to compute MCID scores included the average change method, minimum detectable change approach, change difference calculation, and receiver operating characteristic (ROC) analysis. Area under the ROC curve (AUC) analysis has been shown to inform the accuracy at which the MCID value can distinguish responders from nonresponders and was analyzed for each instrument. RESULTS: For the first time, ranges of MCID values after SCS were established for MPQ (1-2.3) and PCS (1.9-13.6). One-year MCID values were defined for all indications: NRS (range 0.9-2.7), ODI (3.5-6.9), and BDI (2-5.9). AUC values were significant for NRS (0.78, p < 0.001), ODI (0.71, p = 0.003), MPQ (0.74, p < 0.001), and PCS (0.77, p < 0.001), indicating notable accuracy for distinguishing satisfied patients. CONCLUSIONS: This was the first study to successfully determine MCID values for two prominent instruments, MPQ and PCS, used to assess pain after SCS surgery. Additionally, previously established MCID values for ODI, BDI, and the visual analog scale for patients with FBSS at 6 months after treatment were explored at 12 months for the most common indications for SCS. These data may better inform physicians of patient response to and success with SCS therapy.
引用
- Sabourin S, Tram J, Sheldon BL, et al. Defining minimal clinically important differences in pain and disability outcomes of patients with chronic pain treated with spinal cord stimulation. J Neurosurg Spine. 2021. PMID: 34087802. doi:10.3171/2020.11.SPINE201431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。